Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Perspective Therapeutics, Inc.

< Previous 1 2 Next >
Perspective Therapeutics to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Data Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Business Highlights and Report Third Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming Investor Conferences in November
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Presents Updates at the 37th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Begins Shipping Investigational Products from State-of-the-Art Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy [212Pb]VMT01 Based on Data Presented at the 21st International Congress of the Society for Melanoma Research
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the 21st International Congress of the Society for Melanoma Research
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Presents at the World Molecular Imaging Congress 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate in Upcoming Investor Conferences in September
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at Upcoming Investor Conferences in August
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces Inclusion in the Russell 3000® Index
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces 1-for-10 Reverse Stock Split
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Presents at the Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at Upcoming May Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at Upcoming April Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Announces $87.4 Million Private Placement
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Participate at Upcoming Investor Conferences
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Perspective Therapeutics, Inc.
Via GlobeNewswire
Perspective Therapeutics Introduces “Pre-Targeting” Theranostic Technology Platform
From Perspective Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.